Skip to main content
main-content

01.03.2018 | Heart Failure (W Tang, Section Editor) | Ausgabe 3/2018

Current Treatment Options in Cardiovascular Medicine 3/2018

Immune Modulation in Heart Failure: the Promise of Novel Biologics

Zeitschrift:
Current Treatment Options in Cardiovascular Medicine > Ausgabe 3/2018
Autoren:
MD Paulino Alvarez, MD PhD Alexandros Briasoulis
Wichtige Hinweise
This article is part of the Topical Collection on Heart Failure

Abstract

Purpose of review

Immune system activation plays a central role in heart failure progression. Large-scale immune modulatory clinical trials targeting tumor necrosis factor-α and broad spectrum immune modulation have been negative. The objective of this review is to highlight past, present, and what is in the horizon for the immunomodulation in heart failure with a focus of biologics.

Recent findings

Strategies targeting interleukin-1 pathway are currently undergoing clinical evaluation and data from pilot studies are promising. The potential of cell therapy for immune modulation is increasingly recognized in clinical trials. Strategies targeting anti-cardiac antibodies such as immunoadsorption and intravenous immunoglobulin have been used in clinical practice with positive outcomes but large pragmatic clinical trials are lacking. The use of an aptamer to block anti-cardiac antibodies is undergoing phase 1 clinical evaluation. Promising targets include inflammasomes, toll-like receptors, chemokines, natural killer cells, and macrophages.

Summary

Large-scale immune modulatory clinical trials have been negative. Nevertheless, the experience gained from them along with increasing understanding of molecular mechanisms of immune pathophysiology in heart failure is leading to rapid recognition of new therapeutic targets and approaches.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2018

Current Treatment Options in Cardiovascular Medicine 3/2018 Zur Ausgabe

Coronary Artery Disease (D Feldman and V Voudris, Section Editors)

Spontaneous Coronary Artery Dissection: Diagnosis and Management

Arrhythmia (G Upadhyay, Section Editor)

Ablation Approaches for Ventricular Fibrillation

Coronary Artery Disease (D Feldman and V Voudris, Section Editors)

Timing and Outcomes of PCI in the TAVR Era

  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Kardiologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Kardiologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise